Ian has over?35?years of international experience in management and transactions within the life sciences sector. He?is chairman of?Bioventix?plc?and a non-executive director?at?Clinigen?Group plc.?Currently,?he is also?an operating partner?at?London-based Advent Life Sciences LLP, a leading life science?venture investor.
Ian previously spent eight years as CEO of the privately held?anti-fungal drug development company F2G Limited and before that?was?CEO of the?oncology R&D company, Chroma Therapeutics Limited. Prior to that, he was senior vice president, business development at UK biotechnology company?Celltech?Group plc.
Ian has worked extensively in licensing, mergers and acquisitions, and market development in the UK, Europe, and the US and holds a BSc (Hons) from University College London and an MBA from Boston University.
Location
Oxford, United Kingdom
This person is not in the org chart
This person is not in any teams
This person is not in any offices